BioSpace News Archive

Transaction concludes with the launch of “Awakn Clinics Oslo AS” as part of Awakn Life Sciences Nordic Expansion.

Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients.

Gator Bio, Inc. announced the launch of the Gator™ SMAP probe and Gator™ mFC probe for GatorPrime and GatorPlus biolayer interferometry (BLI) systems today.

Halomine™ Inc., a pioneer in advanced technology for managing surfaces and providing long term protection against viruses, bacteria, and fungi, today announced that it has received a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II grant for $1M to advance their flagship product that can provide residual antimicrobial protection against a wide variety of dangerous pathogens.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and IVUS solutions, today announced that a worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions.

ChoiceSpine LLC, a privately-held spinal device manufacturer based in Knoxville, TN, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the Triton Sacroiliac Joint Fixation System.

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the first round of 16 highly anticipated late-breaking clinical trial results at VIVA121 hosted at Wynn Las Vegas.

IntelGenx Technologies Corp. announces that it has received final approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange.

MedSource Labs announced that the VeroTrue™ Conventional IV Catheter, long trusted by healthcare providers outside of the U.S., is now available domestically.

Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”).